60 Degrees Pharmaceuticals (SXTP) Cost of Revenue (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Cost of Revenue of $85715.0 for Q1 2026, up 16.98% year-over-year from $73272.0 in Q1 2025, and down 28.97% quarter-over-quarter from $120682.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Cost of Revenue (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Cost of Revenue for 5 consecutive years, with $85715.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 16.98% year-over-year to $85715.0; the TTM figure through Mar 2026 stood at $794138.0 (up 102.28% YoY), while the FY2025 annual figure was $781695.0, up 103.16% from the prior year.
- Cost of Revenue eased to $85715.0 in Q1 2026 per SXTP's latest filing, from $120682.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $537690.0 in Q3 2025 and bottomed at $50051.0 in Q2 2025.
- Historically, Cost of Revenue has averaged $129310.1 across 5 years, with a median of $90922.5 in 2022.
- Annual changes were most pronounced in 2024 — Cost of Revenue tumbled 51.32% — and 2025, when it surged 381.43%.
- 60 Degrees Pharmaceuticals' Cost of Revenue stood at $162835.0 in 2022, then dropped by 10.18% to $146257.0 in 2023, then retreated by 19.27% to $118077.0 in 2024, then gained by 2.21% to $120682.0 in 2025, then retreated by 28.97% to $85715.0 in 2026.
- Business Quant data shows SXTP's Cost of Revenue at $85715.0 in Q1 2026, $120682.0 in Q4 2025, and $537690.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 151,100.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85,715.00 |
| Mar 31, 2026 | 85,715.00 |
| Dec 31, 2025 | 120,682.00 |
| Dec 31, 2025 | 120,682.00 |
| Sep 30, 2025 | 537,690.00 |
| Sep 30, 2025 | 537,690.00 |
| Jun 30, 2025 | 50,051.00 |
| Jun 30, 2025 | 50,051.00 |
| Mar 31, 2025 | 73,272.00 |
| Mar 31, 2025 | 73,272.00 |
| Dec 31, 2024 | 118,077.00 |
| Dec 31, 2024 | 118,077.00 |
| Sep 30, 2024 | 111,687.00 |
| Sep 30, 2024 | 111,687.00 |
| Jun 30, 2024 | 89,564.00 |
| Jun 30, 2024 | 89,564.00 |
| Mar 31, 2024 | 65,437.00 |
| Mar 31, 2024 | 65,437.00 |
| Dec 31, 2023 | 146,257.00 |
| Dec 31, 2023 | 146,257.00 |